Comparative survival outcomes between EGFR-wildtype and EGFR-mutant lung adenocarcinoma following neoadjuvant chemoimmunotherapy: a retrospective cohort study from national cancer center in China.

ABSTRACT:

Background

The efficacy of neoadjuvant chemoimmunotherapy (NCI) in resectable epidermal growth factor receptor-mutant (EGFR-mutant) lung adenocarcinoma (LUAD) remains controversial. This study aimed to compare the clinical efficacy, survival outcomes, and recurrence patterns between EGFR-wildtype and EGFR-mutant clinically stage I-III LUAD patients following NCI.

Methods

This retrospective study enrolled 97 patients (65 in the EGFR-wildtype group and 32 in the EGFR-mutant group). After balancing baseline characteristics via propensity score matching (PSM) with a 2:1 ratio, perioperative outcomes, pathological response rates, survival rates, and recurrence patterns were compared between the two groups.

Results

Post-PSM (EGFR-wildtype: n=50; EGFR-mutant: n=30), the EGFR

SUBMITTER: Wu S 

PROVIDER: S-EPMC12541655 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature